HCA Healthcare (NYSE:HCA) Releases FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 24.050-25.850 for the period, compared to the consensus EPS estimate of 24.610. The company issued revenue guidance of $72.8 billion-$75.8 billion, compared to the consensus revenue estimate of $74.8 billion.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on HCA. Morgan Stanley lowered their price objective on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $392.00 price objective on shares of HCA Healthcare in a report on Tuesday, October 1st. StockNews.com downgraded shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Oppenheimer upped their target price on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Finally, TD Cowen dropped their target price on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $385.27.

HCA Healthcare Trading Down 4.0 %

NYSE HCA opened at $312.51 on Friday. The firm’s fifty day simple moving average is $313.49 and its 200-day simple moving average is $352.62. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare has a 1-year low of $279.93 and a 1-year high of $417.14. The company has a market capitalization of $79.16 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.52% and a return on equity of 520.98%. During the same period in the prior year, the business earned $5.90 earnings per share. As a group, sell-side analysts anticipate that HCA Healthcare will post 21.75 earnings per share for the current fiscal year.

Insider Transactions at HCA Healthcare

In other news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the transaction, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the transaction, the insider now owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.